CFI-402257
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CFI-402257, covering 2024-06-26 to 2025-05-18. Get the full timeline:
Most recent: Clinical Trial Update: CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer [Phase 1, Phase 2]